Skip to main content

Outlook Therapeutics, Inc.

corporate_fare Company Profile

Outlook Therapeutics, Inc.

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora. Outlook Therapeutics, Inc. was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

Exchange: NASDAQSector: Life Sciences

show_chartPrice Chart

Loading chart...

feed OTLK - Latest Insights

OTLK
Apr 23, 2026, 4:30 PM EDT
Filing Type: 8-K
Importance Score:
8
OTLK
Apr 23, 2026, 7:30 AM EDT
Filing Type: 424B5
Importance Score:
9
OTLK
Apr 21, 2026, 4:15 PM EDT
Filing Type: 8-K
Importance Score:
7
OTLK
Apr 07, 2026, 4:15 PM EDT
Filing Type: 8-K
Importance Score:
8
OTLK
Apr 07, 2026, 8:55 AM EDT
Source: Reuters
Importance Score:
8
OTLK
Mar 25, 2026, 5:04 PM EDT
Filing Type: 8-K
Importance Score:
8
OTLK
Mar 24, 2026, 5:52 PM EDT
Filing Type: 424B5
Importance Score:
9
OTLK
Mar 23, 2026, 5:18 PM EDT
Filing Type: 424B5
Importance Score:
9
OTLK
Mar 16, 2026, 9:00 AM EDT
Filing Type: 8-K
Importance Score:
8
OTLK
Mar 11, 2026, 5:53 PM EDT
Source: Wiseek News
Importance Score:
7
OTLK
Mar 05, 2026, 5:01 PM EST
Filing Type: 8-K
Importance Score:
8
OTLK
Feb 18, 2026, 5:01 PM EST
Filing Type: 8-K
Importance Score:
9
OTLK
Feb 17, 2026, 5:01 PM EST
Filing Type: 10-Q
Importance Score:
9
OTLK
Feb 17, 2026, 8:30 AM EST
Filing Type: 8-K
Importance Score:
8
OTLK
Feb 11, 2026, 5:00 PM EST
Filing Type: 8-K
Importance Score:
8